Inhibition of induced chemoresistance by cotreatment with (E)-5-(2-bromovinyl)-2'-deoxyuridine (RP101). 2003

Rudolf Fahrig, and Jörg-Christian Heinrich, and Bernd Nickel, and Falk Wilfert, and Christina Leisser, and Georg Krupitza, and Christian Praha, and Denise Sonntag, and Beate Fiedler, and Harry Scherthan, and Heinrich Ernst
RESprotect, Dresden, Germany. fahrig@resprotect.de

Induced chemoresistance leads to the reduction of apoptotic responses. Although several drugs are in development that circumvent or decrease existing chemoresistance, none has the potential to prevent or reduce its induction. Here, we present data from a drug that could perhaps fill this gap. Cotreatment of chemotherapy with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU, RP101) prevented the decrease of apoptotic effects during the course of chemotherapy and reduced nonspecific toxicity. Amplification of chemoresistance genes (Mdr1 and Dhfr) and overexpression of gene products involved in proliferation (DDX1) or DNA repair (UBE2N and APEX) were inhibited, whereas activity of NAD(P)H: quinone oxidoreductase 1 (NQO1) was enhanced. During recovery, when treatment was with BVDU only, microfilamental proteins were up-regulated, and proteins involved in ATP generation or cell survival (STAT3 and JUN-D) were down-regulated. That way, in three different rat tumor models, the antitumor efficiency of chemotherapy was optimized, and toxic side effects were reduced. Because of these beneficial properties of BVDU, a clinical pilot Phase I/II study with five human tumor entities has been started at the University of Dresden (Dresden, Germany). So far, no unwanted side effects have been observed.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008942 Mitoxantrone An anthracenedione-derived antineoplastic agent. Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D001973 Bromodeoxyuridine A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors. BUdR,BrdU,Bromouracil Deoxyriboside,Broxuridine,5-Bromo-2'-deoxyuridine,5-Bromodeoxyuridine,NSC-38297,5 Bromo 2' deoxyuridine,5 Bromodeoxyuridine,Deoxyriboside, Bromouracil
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D000077235 Vinorelbine A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES. 5'-Nor-anhydrovinblastine,KW 2307,KW-2307,Navelbine,Vinorelbine Tartrate,5' Nor anhydrovinblastine,KW2307

Related Publications

Rudolf Fahrig, and Jörg-Christian Heinrich, and Bernd Nickel, and Falk Wilfert, and Christina Leisser, and Georg Krupitza, and Christian Praha, and Denise Sonntag, and Beate Fiedler, and Harry Scherthan, and Heinrich Ernst
January 1983, Nucleic acids symposium series,
Rudolf Fahrig, and Jörg-Christian Heinrich, and Bernd Nickel, and Falk Wilfert, and Christina Leisser, and Georg Krupitza, and Christian Praha, and Denise Sonntag, and Beate Fiedler, and Harry Scherthan, and Heinrich Ernst
January 2005, Medicinal research reviews,
Rudolf Fahrig, and Jörg-Christian Heinrich, and Bernd Nickel, and Falk Wilfert, and Christina Leisser, and Georg Krupitza, and Christian Praha, and Denise Sonntag, and Beate Fiedler, and Harry Scherthan, and Heinrich Ernst
April 1990, Biochemical Society transactions,
Rudolf Fahrig, and Jörg-Christian Heinrich, and Bernd Nickel, and Falk Wilfert, and Christina Leisser, and Georg Krupitza, and Christian Praha, and Denise Sonntag, and Beate Fiedler, and Harry Scherthan, and Heinrich Ernst
June 1988, Journal of chromatography,
Rudolf Fahrig, and Jörg-Christian Heinrich, and Bernd Nickel, and Falk Wilfert, and Christina Leisser, and Georg Krupitza, and Christian Praha, and Denise Sonntag, and Beate Fiedler, and Harry Scherthan, and Heinrich Ernst
June 1998, Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians,
Rudolf Fahrig, and Jörg-Christian Heinrich, and Bernd Nickel, and Falk Wilfert, and Christina Leisser, and Georg Krupitza, and Christian Praha, and Denise Sonntag, and Beate Fiedler, and Harry Scherthan, and Heinrich Ernst
May 1981, Proceedings of the National Academy of Sciences of the United States of America,
Rudolf Fahrig, and Jörg-Christian Heinrich, and Bernd Nickel, and Falk Wilfert, and Christina Leisser, and Georg Krupitza, and Christian Praha, and Denise Sonntag, and Beate Fiedler, and Harry Scherthan, and Heinrich Ernst
May 1992, Fundamental and applied toxicology : official journal of the Society of Toxicology,
Rudolf Fahrig, and Jörg-Christian Heinrich, and Bernd Nickel, and Falk Wilfert, and Christina Leisser, and Georg Krupitza, and Christian Praha, and Denise Sonntag, and Beate Fiedler, and Harry Scherthan, and Heinrich Ernst
August 1984, The Journal of antimicrobial chemotherapy,
Rudolf Fahrig, and Jörg-Christian Heinrich, and Bernd Nickel, and Falk Wilfert, and Christina Leisser, and Georg Krupitza, and Christian Praha, and Denise Sonntag, and Beate Fiedler, and Harry Scherthan, and Heinrich Ernst
January 1987, Nucleic acids symposium series,
Rudolf Fahrig, and Jörg-Christian Heinrich, and Bernd Nickel, and Falk Wilfert, and Christina Leisser, and Georg Krupitza, and Christian Praha, and Denise Sonntag, and Beate Fiedler, and Harry Scherthan, and Heinrich Ernst
August 1979, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!